Immune to Cancer: The CRI Blog
-
Immunotherapy Shines at ASH and ESMO IO Conferences
Two conferences, one in America and one in Europe, highlight immunotherapy's continued progress and the important contributions…
-
CAR T Cell Immunotherapy Approved for Adult Non-Hodgkin Lymphoma Patients
FDA approves new immunotherapy–Yescarta (axicabtagene ciloleucel)–for adult patients with relapsed or refractory non-Hodgkin large B cell lymphoma.
-
Sergei G’s Immunotherapy Story
Lymphoma The whole procedure is very well orchestrated…it’s almost like a CIA exploration. Sergei’s Story When doctors… -
Paul M’s Immunotherapy Story
Lymphoma | Diagnosed 2012 When I say my life changed, I don’t mean gradually; it changed immediately. Paul’s… -
Pembrolizumab Approved for Children and Adults with Hard-to-Treat Hodgkin Lymphoma
Pembrolizumab is second anti-PD-1 drug approved for adults with cHL, first for any childhood cancer
-
Michael R’s Immunotherapy Story
Lymphoma | Diagnosed 2008 Some of the things that we’ve done over the last four years, I think,… -
Young Adults “Chasing Cancer”
Guest blogger Ariella Chivil recaps her visit at The Washington Post Chasing Cancer Summit.
-
CRI, LRF Team Up to Improve How Doctors Assess Lymphoma Patients Treated with Immunotherapy
LYRIC might provide a better way to gauge immunotherapy responses in lymphoma patients. Clinical trials are essential…
-
ASCO 2016 Update: Advances in Immunotherapy for Lung and Blood Cancers
Combination checkpoints, improved CAR T cells show promise.